The startup develops plant-based pharmaceuticals by utilizing drug discovery research and unique delivery methods to introduce standardized plant active pharmaceutical ingredients (APIs) directly into the human bloodstream. This approach enhances access to effective plant-derived treatments, addressing the limitations of traditional pharmaceutical options.
Funding
$6.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional pharmaceutical treatments often have limitations, and there is a growing need for effective plant-derived medicines that can be directly introduced into the bloodstream. Current methods may not fully harness the potential of plant-based active pharmaceutical ingredients (APIs) for optimal therapeutic outcomes.
Solution
Kensana Health is a phyto-pharmaceutical company that develops plant-based pharmaceuticals by utilizing drug discovery research and unique delivery methods to introduce standardized plant active pharmaceutical ingredients (APIs) directly into the human bloodstream. The company focuses on developing Environmentally Modified Organisms (EMOs) and standardized growing techniques to ensure consistent and high-quality biological APIs. Kensana Health leverages its research and partnerships to create innovative plant-based healthcare solutions, particularly in wound management and other therapeutic areas. By integrating technology with naturally occurring compounds, Kensana Health aims to transform modern medicine and provide enhanced access to effective plant-derived treatments.
Target Audience
The primary target audience includes patients seeking alternative and plant-based pharmaceutical treatments, healthcare providers specializing in wound management, and pharmaceutical companies looking to expand their portfolios with innovative plant-derived medicines.
Features
- Development of Environmentally Modified Organisms (EMOs) for optimized plant growth and API production.
- Standardized growing techniques to ensure consistent biological API quality within +/- 10% parameters.
- Proprietary intellectual property portfolio focused on skin integument and drug discovery through standardized plant APIs.
- Vertically integrated phyto-pharmaceutical operations.
- Research and development in controlled environment systems to optimize growing conditions.
- Partnerships with multinational phytopharmaceutical companies and research institutions.
- Clinical trials for rare diseases and wound management solutions.